News Update :

Propoxyphene removed from US Market by FDA

Friday, November 19, 2010

Here the Propoxyphene news update which FDA has asked that propoxyphene, (brand names Darvon and Darvocet, Xanodyne Pharmaceuticals) be removed from the US market. Propoxyphene has been pulled from the market by the FDA because of heart risks associated with the drugs. The FDA sought the withdrawal after receiving new data showing that the drug put patients at risk for potentially fatal heart rhythm abnormalities, the agency said.

The news is significant because propoxyphene (sold as Darvon, Darvocet, and multiple generic forms of the ingredient) is a widely used opioid analgesic. An estimated 10 million patients have used this drug.

Users of Practice Fusion can quickly identify their patients who are on propoxyphene, in order to identify and (if appropriate) contact patients in order to discuss alternatives. As this news becomes public-headline material, it is highly likely that practitioners everywhere will be fielding calls about this.

In order to identify patients taking propoxyphene from Practice Fusion, go to the “Reports” section, and under the Reports tab select “Medication report”. Double clicking that item will open up the Medication report in its own tab. In the Search field, enter “propoxyphene” and click the “Run Report” button – a list of all the practice’s patients on any drug containing propoxyphene (brand or generic) will be generated. The report can be printed, if desired, for action.
Share this Article on :


Post a Comment


© Copyright Kezong News 2010 -2011 | Design by Herdiansyah Hamzah | Published by Borneo Templates | Powered by